Eider Valle-Encinas
Scientific Business Development Manager HUB Organoids (A Merck Company)
Seminars
Monday 3rd November 2025
Using Patient-Derived Organoids to Prioritize ADC Clinical Development & Derisk Early Toxicities
1:30 pm
- Exploring how utilizing HUB Organoid Technology allows to develop patient-derived organoids relevant with high fidelity to the original tumor
- Leveraging HUB Organoids to de-risk preclinical development of ADCs, prioritize indications, uncover target independent toxicities, and complement biomarker strategy
- Assessing how the next frontier for ADC organoids will see mode of action studies performed to optimize clinical candidates and prioritize patient selection
